Heron Therapeutics, Inc.
HRTX· Nasdaq
HRTXHeron Therapeutics, Inc.
Filed Feb 28, 2022 · 10-K · 59 days after period end · 0001564590-22-007618
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $20.66M | $20.61M | $35.08M | $28.84M |
| Net Income | -$54.65M | -$62.28M | -$57.92M | -$49.56M |
| EPS Diluted | — | -$0.68 | -$0.65 | -$0.63 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
ended Dec 31, 2021 · filed Feb 28, 2022 · 59 d after period end
